Efficacy, equivalence and operability of switching to a combination of budesonide, glycopyrronium, and formoterol in patients with COPD and ACO

Efficacy, equivalence and operability of switching to a combination of budesonide, glycopyrronium, and formoterol in patients with COPD and ACO - Efficacy, equivalence and operability of switching to a combination of budesonide, glycopyrronium, and formoterol in patients with COPD and ACO

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049879

Enrollment

Registered

2022-12-23

Start date

2020-12-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Breztri for patients requiring ICS, LABA, or LAMA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD or ACO patients requiring ICS, LABA and LAMA Patients who can give consent

Exclusion criteria

Exclusion criteria: 1) Under 40 years old 2) Patients who have difficulty inhaling by theirself 3) Patients for whom the physician determines that pulmonary function testing is impossible or inaccurate for any reason (e.g., hearing loss, pregnancy, etc.) 4) Patients whose QoL or lung function may be affected during the study period, as determined by the physician: e.g., patients with end-stage cancer, severe heart failure, liver cirrhosis, respiratory failure, etc. 5) Patients who cannot use ICS or LABA or LAMA

Design outcomes

Primary

Measure	Time frame
Efficacy, adverse events, inhalation maneuverability, and adherence before and after switching to Breztri (a combination of budesonide, glycopyrronium, and formoterol) in patients with COPD or ACO requiring an ICS, LABA, and LAMA.	—

Secondary

Measure	Time frame
Comparison with Trelegy in patients switching from Trelegy	—

Countries

Japan

Contacts

Public ContactMasato Muraki

Kindai University Nara Hospital Department of Respiratory Medicine and Allergology

muraki-m@med.kindai.ac.jp0743-77-0880

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026